186 related articles for article (PubMed ID: 17190642)
1. Keratoacanthomas associated with sorafenib therapy.
Kong HH; Cowen EW; Azad NS; Dahut W; Gutierrez M; Turner ML
J Am Acad Dermatol; 2007 Jan; 56(1):171-2. PubMed ID: 17190642
[No Abstract] [Full Text] [Related]
2. [Sorafenib-induced multiple eruptive keratoacanthomas].
Jantzem H; Dupre-Goetghebeur D; Spindler P; Merrer J
Ann Dermatol Venereol; 2009 Dec; 136(12):894-7. PubMed ID: 20004316
[TBL] [Abstract][Full Text] [Related]
3. Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Marquez CB; Smithberger EE; Bair SM; Wenham RM; Fenske NA; Glass LF; Cherpelis BS
Cancer Control; 2009 Jan; 16(1):66-9. PubMed ID: 19078932
[No Abstract] [Full Text] [Related]
4. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
[No Abstract] [Full Text] [Related]
5. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sibaud V; Delord JP; Chevreau C
Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
[TBL] [Abstract][Full Text] [Related]
6. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib-induced destructive thyroiditis.
Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
[No Abstract] [Full Text] [Related]
8. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Arnault JP; Wechsler J; Escudier B; Spatz A; Tomasic G; Sibaud V; Aractingi S; Grange JD; Poirier-Colame V; Malka D; Soria JC; Mateus C; Robert C
J Clin Oncol; 2009 Aug; 27(23):e59-61. PubMed ID: 19597016
[No Abstract] [Full Text] [Related]
9. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
10. [Squamous cell carcinoma in a patient receiving sorafenib].
Adnot-Desanlis L; Bernard P; Reguiaï Z
Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
13. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
14. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
15. Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.
Rini BI
Clin Adv Hematol Oncol; 2011 Apr; 9(4):337-8. PubMed ID: 21558996
[No Abstract] [Full Text] [Related]
16. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
Bellini E; Pia A; Brizzi MP; Tampellini M; Torta M; Terzolo M; Dogliotti L; Berruti A
Ann Oncol; 2011 Apr; 22(4):988-990. PubMed ID: 21321087
[No Abstract] [Full Text] [Related]
17. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Wollenberg A; Staehler M; Eames T
Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
[TBL] [Abstract][Full Text] [Related]
18. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Smith KJ; Haley H; Hamza S; Skelton HG
Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
20. Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Lopez V; Pinazo I; Marti N; Monteagudo C; Jorda E
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):959-60. PubMed ID: 18785888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
